Nuclear medicine imaging of endocrine neoplasms

Ka Kit Wong, Asha Kandathil, Maria Cristina Marzola, Milton D. Gross, Domenico Rubello

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Endocrine tumors are hormonally active benign or malignant neoplasms arising within endocrine organs or from specialized cells of the amine precursor uptake and decarboxylation system. The detection rate of these tumors is increasing as a result of sensitive biochemical tests and high-resolution diagnostic imaging. Medical imaging has become a key component in the diagnosis and staging of endocrine malignancies; however, despite the impressive advances in computed tomography (CT) and MRI, detection of small primary tumors and metastases continues to be a challenge. Functional imaging techniques use radiopharmaceuticals targeted at unique tumor cellular processes in order to provide sensitive and highly specific whole-body imaging. Functional imaging allows prediction of the efficacy of radionuclide or receptor-based therapies and surveillance after therapy. Advances in imaging have not been limited to radiopharmaceuticals. Hybrid scanner technology in the form of PET/CT and single photon emission computed tomography (SPECT)/CT, designed to combine functional images with anatomic maps, has further improved the diagnostic accuracy. High-resolution hybrid imaging when deployed with novel PET and SPECT radiopharmaceuticals has the potential to dramatically change, individualize, and optimize imaging plans based on the histological grade, degree of differentiation, and genetic profile of each patient's endocrine neoplasm.

Original languageEnglish (US)
Pages (from-to)1-19
Number of pages19
JournalNuclear Medicine Communications
Volume35
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Nuclear Medicine
Radiopharmaceuticals
Neoplasms
Diagnostic Imaging
APUD Cells
Multimodal Imaging
Whole Body Imaging
Single-Photon Emission-Computed Tomography
Radioisotopes
Tomography
Neoplasm Metastasis
Technology
Therapeutics
Single Photon Emission Computed Tomography Computed Tomography

Keywords

  • Adrenocortical cancer
  • Anaplastic thyroid cancer
  • Medullary thyroid cancer
  • Merkel cell cancer
  • Neuroblastoma
  • Neuroendocrine tumor
  • Paraganglioma
  • Parathyroid carcinoma
  • Pheochromocytoma
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Nuclear medicine imaging of endocrine neoplasms. / Wong, Ka Kit; Kandathil, Asha; Marzola, Maria Cristina; Gross, Milton D.; Rubello, Domenico.

In: Nuclear Medicine Communications, Vol. 35, No. 1, 01.01.2014, p. 1-19.

Research output: Contribution to journalReview article

Wong, Ka Kit ; Kandathil, Asha ; Marzola, Maria Cristina ; Gross, Milton D. ; Rubello, Domenico. / Nuclear medicine imaging of endocrine neoplasms. In: Nuclear Medicine Communications. 2014 ; Vol. 35, No. 1. pp. 1-19.
@article{daf8ae07f3094494828f40d3ea432160,
title = "Nuclear medicine imaging of endocrine neoplasms",
abstract = "Endocrine tumors are hormonally active benign or malignant neoplasms arising within endocrine organs or from specialized cells of the amine precursor uptake and decarboxylation system. The detection rate of these tumors is increasing as a result of sensitive biochemical tests and high-resolution diagnostic imaging. Medical imaging has become a key component in the diagnosis and staging of endocrine malignancies; however, despite the impressive advances in computed tomography (CT) and MRI, detection of small primary tumors and metastases continues to be a challenge. Functional imaging techniques use radiopharmaceuticals targeted at unique tumor cellular processes in order to provide sensitive and highly specific whole-body imaging. Functional imaging allows prediction of the efficacy of radionuclide or receptor-based therapies and surveillance after therapy. Advances in imaging have not been limited to radiopharmaceuticals. Hybrid scanner technology in the form of PET/CT and single photon emission computed tomography (SPECT)/CT, designed to combine functional images with anatomic maps, has further improved the diagnostic accuracy. High-resolution hybrid imaging when deployed with novel PET and SPECT radiopharmaceuticals has the potential to dramatically change, individualize, and optimize imaging plans based on the histological grade, degree of differentiation, and genetic profile of each patient's endocrine neoplasm.",
keywords = "Adrenocortical cancer, Anaplastic thyroid cancer, Medullary thyroid cancer, Merkel cell cancer, Neuroblastoma, Neuroendocrine tumor, Paraganglioma, Parathyroid carcinoma, Pheochromocytoma, Thyroid cancer",
author = "Wong, {Ka Kit} and Asha Kandathil and Marzola, {Maria Cristina} and Gross, {Milton D.} and Domenico Rubello",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MNM.0000000000000021",
language = "English (US)",
volume = "35",
pages = "1--19",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Nuclear medicine imaging of endocrine neoplasms

AU - Wong, Ka Kit

AU - Kandathil, Asha

AU - Marzola, Maria Cristina

AU - Gross, Milton D.

AU - Rubello, Domenico

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Endocrine tumors are hormonally active benign or malignant neoplasms arising within endocrine organs or from specialized cells of the amine precursor uptake and decarboxylation system. The detection rate of these tumors is increasing as a result of sensitive biochemical tests and high-resolution diagnostic imaging. Medical imaging has become a key component in the diagnosis and staging of endocrine malignancies; however, despite the impressive advances in computed tomography (CT) and MRI, detection of small primary tumors and metastases continues to be a challenge. Functional imaging techniques use radiopharmaceuticals targeted at unique tumor cellular processes in order to provide sensitive and highly specific whole-body imaging. Functional imaging allows prediction of the efficacy of radionuclide or receptor-based therapies and surveillance after therapy. Advances in imaging have not been limited to radiopharmaceuticals. Hybrid scanner technology in the form of PET/CT and single photon emission computed tomography (SPECT)/CT, designed to combine functional images with anatomic maps, has further improved the diagnostic accuracy. High-resolution hybrid imaging when deployed with novel PET and SPECT radiopharmaceuticals has the potential to dramatically change, individualize, and optimize imaging plans based on the histological grade, degree of differentiation, and genetic profile of each patient's endocrine neoplasm.

AB - Endocrine tumors are hormonally active benign or malignant neoplasms arising within endocrine organs or from specialized cells of the amine precursor uptake and decarboxylation system. The detection rate of these tumors is increasing as a result of sensitive biochemical tests and high-resolution diagnostic imaging. Medical imaging has become a key component in the diagnosis and staging of endocrine malignancies; however, despite the impressive advances in computed tomography (CT) and MRI, detection of small primary tumors and metastases continues to be a challenge. Functional imaging techniques use radiopharmaceuticals targeted at unique tumor cellular processes in order to provide sensitive and highly specific whole-body imaging. Functional imaging allows prediction of the efficacy of radionuclide or receptor-based therapies and surveillance after therapy. Advances in imaging have not been limited to radiopharmaceuticals. Hybrid scanner technology in the form of PET/CT and single photon emission computed tomography (SPECT)/CT, designed to combine functional images with anatomic maps, has further improved the diagnostic accuracy. High-resolution hybrid imaging when deployed with novel PET and SPECT radiopharmaceuticals has the potential to dramatically change, individualize, and optimize imaging plans based on the histological grade, degree of differentiation, and genetic profile of each patient's endocrine neoplasm.

KW - Adrenocortical cancer

KW - Anaplastic thyroid cancer

KW - Medullary thyroid cancer

KW - Merkel cell cancer

KW - Neuroblastoma

KW - Neuroendocrine tumor

KW - Paraganglioma

KW - Parathyroid carcinoma

KW - Pheochromocytoma

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=84889243841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889243841&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000021

DO - 10.1097/MNM.0000000000000021

M3 - Review article

C2 - 24201551

AN - SCOPUS:84889243841

VL - 35

SP - 1

EP - 19

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 1

ER -